MicroRNA-429在妇科恶性肿瘤中的研究进展

李栗扬; 徐鹏; 王蓓蒂; 高爽; 郭钰; 匡野

doi:10.16766/j.cnki.issn.1674-4152.001973

MicroRNA-429在妇科恶性肿瘤中的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.001973

哈尔滨医科大学附属第二医院妇产科，黑龙江哈尔滨 150086

基金项目:

吴阶平医学基金会临床科研课题项目 320675018061

详细信息

通讯作者:
匡野, E-mail: kuangye-blue@163.com

中图分类号: R737.3 R730
计量
- 文章访问数: 266
- HTML全文浏览量: 106
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-08
- 网络出版日期: 2022-02-16

Research progress of MicroRNA-429 in gynecological malignant tumors

Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China

摘要

摘要: 妇科恶性肿瘤是威胁女性健康的难题，早期诊断及治疗对于其预后来说意义重大。微小核糖核酸(microRNA, miRNA)是参与细胞转录后调控的小型非编码RNA，在细胞正常生理过程及肿瘤发生发展中起关键作用。MicroRNA-429(miR-429)可抑制相关转录遏制物锌指E盒结合同源框1(Zinc E-box-binding homobox 1, ZEB1)和ZEB2的表达影响肿瘤的进展及转移，并通过调控Slug基因的表达，影响E-钙黏蛋白和Snail蛋白等的表达，进而调控肿瘤中的上皮间质转化(epithelial-mesenchymal transition, EMT)，影响着肿瘤的迁移侵袭、预后以及药物敏感性。miR-429在卵巢癌(ovarian cancer)中起到肿瘤促进作用且不利于预后，但其低表达与患者生存率低相关，并且在卵巢癌腹水中发现了miR-429的差异表达，具有潜在临床诊断意义；在宫颈癌(cervical cancer)中起到肿瘤抑制作用；在子宫内膜癌(endometrial cancer)中起到肿瘤促进作用，并且可能具有潜在的诊断价值。现将关于miR-429及其在妇科恶性肿瘤中作用的相关文献进行综述，结合肿瘤发生、侵袭等多方面因素进行讨论，综合分析miR-429在妇科恶性肿瘤的意义，并为进一步研究其在临床应用中的意义提供参考。
- 微小核糖核酸-429 /
- 上皮-间质转化 /
- 卵巢癌 /
- 宫颈癌 /
- 子宫内膜癌
Abstract: Gynecological malignant tumors is a problem that threatens women's health, of which early diagnosis and treatment are of great significance to the prognosis. MicroRNA (miRNA) is a small non-coding RNA involved in post-transcriptional regulation of cells, which plays a key role in the normal physiological processes of cells and the development of tumors. MicroRNA-429 (miR-429) can inhibit the expression of zinc E-box-binding homobox 1 (ZEB1) and ZEB2, which affects tumor progression and metastasis, and regulates Slug Gene expression in order to affects the expression of E-cadherin and Snail protein, and regulates the epithelial-mesenchymal transition (EMT) in tumors, which affects tumor migration, invasion, prognosis, and drug sensitivity. MiR-429 plays a tumor-promoting role in ovarian cancer and is not conducive to the prognosis, but its low expression is associated with low patient survival rates, and the differential expression of miR-429 was found in the ascites of ovarian cancer patients, which has potential clinical diagnostic significance. It plays a role in tumor suppression in cervical cancer role; plays a tumor-promoting role in endometrial cancer, and may have potential diagnostic value in endometrial cancer.The related literature on miR-429 and it's role in gynecological malignancies is reviewed, combined with tumor occurrence, invasion and other factors to discuss, comprehensively analyze the significance of miR-429 in gynecological malignancies, and for the further study significance in clinical application provides reference.
- MicroRNA-429 /
- Epithelial-mesenchymal transition (EMT) /
- Ovarian cancer /
- Cervical cancer /
- Endometrial cancer

HTML全文

参考文献(45)

[1]	OURA K, MORISHITA A, MASAKI T. Molecular and functional roles of microRNAs in the progression of hepatocellular carcinoma—a review[J]. Int J Mol Sci, 2020, 21(21): E8362. doi: 10.3390/ijms21218362
[2]	党树伟, 刘明, 李国东. 微RNA-34a在肝癌中的作用研究进展[J]. 中华肝胆外科杂志, 2016, 7(22): 497-500.
[3]	KUMAR V, GUPTA S, VARMA K, et al. MicroRNA as biomarker in ovarian cancer management: advantages and challenges[J]. DNA Cell Biol, 2020. DOI: 10.1089/dna.2020.6024.Epubaheadofprint.
[4]	ANGIUS A, COSSU-ROCCA P, ARRU C, et al. Modulatory role of microRNAs in triple negative breast cancer with basal-like phenotype[J]. Cancers, 2020, 11(12): E3298. http://www.researchgate.net/publication/346008324_Modulatory_Role_of_microRNAs_in_Triple_Negative_Breast_Cancer_with_Basal-Like_Phenotype
[5]	LILI L N, HUANG A D, ZHANG M, et al. Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes[J]. Cancer Lett, 2018, 428: 184-191. doi: 10.1016/j.canlet.2018.05.001
[6]	余稳稳, 陶瑞雨, 冯学亮, 等. miR-429与肿瘤相关性研究进展[J]. 中华实用诊断与治疗杂志, 2016, 30(10): 950-952. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201610005.htm
[7]	敬剑英, 喻雪琴, 陈芳, 等. microRNA在糖尿病肾病发病机制中的研究进展[J]. 海南医学, 2019, 30(11): 1455-1458. doi: 10.3969/j.issn.1003-6350.2019.11.029
[8]	FU J, PENG L, TAO T, et al. Regulatory roles of the miR-200 family in neurodegenerative diseases[J]. Biomed Pharmacother, 2019, 119: 109409. doi: 10.1016/j.biopha.2019.109409
[9]	HUANG G L, SUN J, LU Y, et al. MiR-200 family and cancer: From a meta-analysis view[J]. Mol Aspects Med, 2019, 70: 57-71. doi: 10.1016/j.mam.2019.09.005
[10]	LIU W, ZHANG K, WEI P, et al. Correlation between miR-200 family overexpression and cancer prognosis[J]. Dis Markers, 2018. DOI: 10.1155/2018/6071826.
[11]	WANG J, WANG C, LI Q, et al. MiR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway[J]. Biomed Pharmacother, 2020, 127: 110215. doi: 10.1016/j.biopha.2020.110215
[12]	ZOU J, LIU L, WANG Q, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1[J]. Am J Transl Res, 2017, 9(3): 1357-1368. http://ajtr.org/files/ajtr0026515.pdf
[13]	FRANKE F C, SLUSARENKO B O, ENGLEITNER T, et al. Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness[J]. Int J Cancer, 2020, 147(6): 1715-1731. doi: 10.1002/ijc.32955
[14]	WANG Y, DONG X, HU B, et al. The effects of Micro-429 on inhibition of cervical cancer cells through targeting ZEB1 and CRKL[J]. Biomed Pharmacother, 2016, 80: 311-321. doi: 10.1016/j.biopha.2016.03.035
[15]	WU L, LIU Y, GUO C, et al. LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway[J]. Cancer Cell Int, 2020, 20: 296. doi: 10.1186/s12935-020-01366-w
[16]	RAMESH V, BRABLETZ T, CEPPI P. Targeting EMT in cancer with repurposed metabolic inhibitors[J]. Trends Cancer, 2020, 6(11): 942-950. doi: 10.1016/j.trecan.2020.06.005
[17]	RANKOVIĆ B, ZIDAR N, ŽLAJPAH M, et al. Epithelial-mesenchymal transition-related microRNAs and their target genes in colorectal cancerogenesis[J]. J Clin Med, 2019, 8(10): 1603. doi: 10.3390/jcm8101603
[18]	ZHANG W, SUN J, CHEN J, et al. Downregulation of miR-95 in gastric cancer promotes EMT via regulation of slug, thereby promoting migration and invasion[J]. Oncol Rep, 2019, 41(2): 1395-1403. http://www.ncbi.nlm.nih.gov/pubmed/30535480
[19]	NI L, LI Z, SHI X, et al. Rosthorin A inhibits non-small cell lung cancer cell growth and metastasis through repressing epithelial-mesenchymal transition via downregulating Slug[J]. Anticancer Drugs, 2020, 31(10): 997-1003. doi: 10.1097/CAD.0000000000000973
[20]	ZONG M, LIU Y, ZHANG K, et al. The effects of miR-429 on cell migration and invasion by targeting Slug in esophageal squamous cell carcinoma[J]. Pathol Res Pract, 2019, 215(9): 152526. doi: 10.1016/j.prp.2019.152526
[21]	YUAN L, BING Z, YAN P, et al. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: a consideration on heterogeneity[J]. Gene, 2019, 716: 144025. doi: 10.1016/j.gene.2019.144025
[22]	陈恩利, 楼俊晓, 王镇, 等. lncRNA GIHCG通过调节miR-429在原发性肝癌发生发展中的作用[J]. 中华全科医学, 2019, 17(5): 779-783. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201905021.htm
[23]	SULIMAN M A, ZHANG Z, NA H, et al. Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family[J]. Int J Mol Med, 2016, 38(3): 776-784. doi: 10.3892/ijmm.2016.2689
[24]	ZHANG L, LIU Q, MU Q, et al. MiR-429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β-catenin signaling pathway[J]. Thorac Cancer, 2020, 11(11): 3126-3138. doi: 10.1111/1759-7714.13620
[25]	ZONG M, LIU Y, ZHANG K, et al. The effects of miR-429 on cell migration and invasion by targeting slug in esophageal squamous cell carcinoma[J]. Pathol Res Pract, 2019, 215(9): 152526. doi: 10.1016/j.prp.2019.152526
[26]	DÊDOVÁ T, BRAICU E I, SEHOULI J, et al. Sialic acid linkage analysis refines the diagnosis of ovarian cancer[J]. Front Oncol, 2019, 9: 261. doi: 10.3389/fonc.2019.00261
[27]	MATHIEU K B, BEDI D G, THROWER S L, et al. Screening for ovarian cancer: imaging challenges and opportunities for improvement[J]. Ultrasound Obstet Gynecol, 2018, 51(3): 293-303. doi: 10.1002/uog.17557
[28]	LI X, CHEN H, WANG S, et al. Tacrolimus induces fibroblasts apoptosis and reduces epidural fibrosis by regulating miR-429 and its target of RhoE[J]. Biochem Biophys Res Commun, 2017, 490(4): 1197-1204. doi: 10.1016/j.bbrc.2017.06.181
[29]	GUAN W, CUI H, HUANG P, et al. MiR-200b/200a/429 cluster stimulates ovarian cancer development by targeting ING5[J]. J Oncol, 2020. DOI: 10.1155/2020/3404059.
[30]	ZHENG H C, ZHAO S, SONG Y, et al. The roles of ING5 expression in ovarian carcinogenesis and subsequent progression: a target of gene therapy[J]. Oncotarget, 2017, 8(61): 103449-103464. doi: 10.18632/oncotarget.21968
[31]	ZÁVESKÝ L, JANDÁKOVÁ E, WEINBERGER V, et al. Ascites-Derived extracellular microRNAs as potential biomarkers for ovarian cancer[J]. Reprod Sci, 2019, 26(4): 510-522. doi: 10.1177/1933719118776808
[32]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[33]	LIU Y, LI L, LI Y, et al. Research progress on tumor-associated macrophages and inflammation in cervical cancer[J]. Biomed Res Int, 2020, 2020: 6842963. DOI: 10.1155/2020/6842963.
[34]	HE J, HUANG B, ZHANG K, et al. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity[J]. Biomed Pharmacother, 2020, 127: 110209. DOI: 10.1016/j.biopha.2020.110209
[35]	SHEN F, ZHENG H, ZHOU L, et al. Overexpression of MALAT1 contributes to cervical cancer progression by acting as a sponge of miR-429. Journal of cellular physiology[J]. J Cell Physiol, 2019, 234(7): 11219-11226. doi: 10.1002/jcp.27772
[36]	STRUZIK J, SZULC-DABROWSKA L. NF-κB signaling in targeting tumor cells by oncolytic viruses-therapeutic perspectives[J]. Cancers(Basel), 2018, 10(11): 426. http://www.mdpi.com/2072-6694/10/11/426/htm
[37]	FAN J Y, FAN Y J, WANG X L, et al. miR-429 is involved in regulation of NF-κBactivity by targeting IKKβ and suppresses oncogenic activity in cervical[J]. FEBS Lett, 2017, 591(1): 118-128. doi: 10.1002/1873-3468.12502
[38]	WEI L, XIONG H, LI W, et al. Upregulation of IL-6 expression in human salivary gland cell line by IL-17 via activation of p38 MAPK, ERK, PI3K/Akt, and NF-κB pathways[J]. J Oral Pathol Med, 2018, 47(9): 847-855. doi: 10.1111/jop.12765
[39]	BUHRMANN C, POPPER B, AGGARWAL B B, et al. Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-β) in articular chondrocytes: Comparison with TNF-α[J]. PLoS One, 2017, 12(11): e0186993. doi: 10.1371/journal.pone.0186993
[40]	中华人民共和国国家健康委员会. 子宫内膜癌诊治规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2020, 6(4): 25-35. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202004006.htm
[41]	RENAUD M C, LE T. No. 291-Epidemiology and investigations for suspected endometrial cancer[J]. J Obstet Gynaecol Can, 2018, 40(9): e703-e711. doi: 10.1016/j.jogc.2018.07.005
[42]	DONKERS H, BEKKERS R, GALAAL K. Diagnostic value of microRNA panel in endometrial cancer: A systematic review[J]. Oncotarget, 2020, 11(21): 2012-2023. http://www.researchgate.net/publication/341665933_Diagnostic_value_of_microRNA_panel_in_endometrial_cancer_A_systematic_review/download
[43]	KOZAK J, WDOWIAK P, MACIEJEWSKI R, et al. Interactions between microRNA-200 family and Sestrin proteins in endometrial cancer cell lines and their significance to anoikis[J]. Mol Cell Biochem, 2019, 459(1-2): 21-34. doi: 10.1007/s11010-019-03547-2
[44]	LIU X, ZHANG J, XIE B, et al. MicroRNA-200 family profile: A promising ancillary tool for accurate cancer diagnosis[J]. Am J Ther, 2016, 32(2): e388-e397.
[45]	GUO C, GAO C, ZHAO D, et al. A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 10-1186. doi: 10.1186/s13046-019-1518-z